Cupid shares fell more than 3% to ₹356.75 on Monday after hitting a fresh lifetime high, as investors appeared to book profits following a sharp rally. According to The Economic Times, the stock rose nearly 1% in early trade to a record high of ₹368.95, extending its gains to over 100% in just three months. However, it soon reversed course, wiping out its intraday gains as profit-taking pressure mounted after the multibagger stock's remarkable performance. Despite today's fall, the stock has delivered stellar returns with 245% gains in 2026 so far, 630% in one year, 7,485% in three years, and an impressive 15,000% over five years.
The stock's performance over extended periods has been particularly impressive, with gains of 7,485% over three years and 15,000% over five years. As reported by The Economic Times, these returns demonstrate Cupid's track record as a significant wealth creator, with the stock demonstrating resilience even as broader market performance has remained subdued. The stock's recent performance includes 16.09% gains in one week, 28.57% in one month, and 242.92% year-to-date. An investment of ₹1 lakh five years ago would have grown to approximately ₹1.51 crore based on the 15,000% return delivered during the period.
In an exchange filing, Cupid Limited announced that its total revenue for Q2 FY27 is expected to exceed ₹200 crore. According to the company's guidance, FY27 revenue guidance has been raised to over ₹800 crore and net profit guidance to more than ₹250 crore. The improved outlook is attributed to strong momentum across healthcare and personal care businesses, growing visibility in institutional and private markets, expansion of domestic FMCG portfolio, and progress towards operationalising the upcoming Palava manufacturing facility. As reported by The Economic Times, the FY27 outlook has been revised upward, supported by strong Q2 FY27 business momentum expected to continue and grow through Q3 and Q4 FY27.
The company has outlined ambitious expansion plans to strengthen its international healthcare business by expanding institutional, government and private-market opportunities across geographies. According to The Economic Times, Cupid plans to build regional manufacturing platforms through the proposed South African venture, creating a potential base for wider international market expansion. The company also plans to explore strategic healthcare opportunities through partnerships and investments that complement Cupid's healthcare and personal care system. The company manufactures and supplies male and female condoms, water-based lubricant jelly and IVD kits, positioning it well for both domestic and international growth.
